Senores Pharma Q1 FY27 Revenue Up 36% to ₹180 Cr

Senores Pharmaceuticals Limited announced its unaudited financial results for the quarter ended June 30, 2026. The company reported a consolidated revenue of ₹180.2 crore, a significant 35.9% year-over-year increase. EBITDA grew by 87% to ₹54 crore, and PAT rose by 56% to ₹31 crore. The strong performance was driven by robust growth in Regulated Markets (up 41.9%) and Emerging Markets (up 29.6%). The company also highlighted a near doubling of its Regulated Markets ANDA portfolio to 58 approved ANDAs, with 23 commercialized. The Emerging Markets business is now cash flow positive with EBITDA margins around 14%. The acquisition of a USFDA-approved manufacturing plant is expected to enhance scalability and margins.